Marpai shareholders approve reverse stock split authorization up to 1:5

Marpai, Inc.

Reverse split ratio authorized between 1:2 and 1:5, implementation by Dec 31, 2023.
Proposal 1 passed with 17,374,153 for, 729,672 against, 1,810 abstentions.
Proposal 2 (adjournment if needed) passed with 17,857,307 for, 246,622 against.
Board discretion to set exact ratio and timing within the authorized range.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Marpai, Inc. shareholders approved Authorization of the Company's Board of the Directors to Amend the Certificate of Incorporation to Effect a Reverse Stock Split of All Outstanding Shares of Class A Common Stock at the 2023-06-26 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2023-06-26

Exact text from the filing

Proposal No. 1 - Authorization of the Company’s Board of the Directors to Amend the Certificate of Incorporation to Effect a Reverse Stock Split of All Outstanding Shares of Class A Common Stock The Company’s stockholders voted to authorize the Company’s Board of Directors to amend the Company’s Certificate of Incorporation, as amended, to effect a reverse split of the Company’s issued and outstanding shares of Class A common stock, $0.0001 par value per share, at a ratio of not less than one-for-two (1:2) and not greater than one-for-five (1:5), to be implemented no later than December 31, 2023, as determined by the Board in its sole discretion: For Against Abstain Broker Non-Votes 17,374,153 729,672 1,810 N/A

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Marpai, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-029850

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.